The US state of Utah, which introduced a preferred prescription drug list in 2007, has reported reduced spending for its medicine-related Medicaid services in the program's first year of $546,000. However, the Utah Department of Health admitted that the amount was less than one sixth of the $2.8-million forecast saving to taxpayers.
The Department's Director, David Sundwall, blamed state legislators for the cost overrun, explaining that amendments to the scheme had allowed physicians to override the preferred drugs more easily than anticipated in the original proposal. The Salt Lake City Tribune also reported that some drugs were only added to the Medicaid list during the course of the year. Mr Sundwall said that lower administrative costs should bring $1.2 million in lower bills next fiscal year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze